Physician profile
John Hirsch
NPI 1255652962
$14,811.03
in general payments reported to CMS, 2019-2025
31 companies · $2,880 in 2025
The $2,880 reported for 2025 was more than what 84% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,601 · 2020: $876 · 2021: $1,520 · 2022: $1,165 · 2023: $4,234 · 2024: $1,535 · 2025: $2,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,599 · Travel and Lodging: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,598.62 |
| Travel and Lodging | $2,050.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,826.60 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Abbott Laboratories | $2,793.06 | 2021-2025 | Proclaim, Eterna, Octrode |
| Relievant Medsystems, INC. | $1,823.87 | 2023 | Intracept |
| Boston Scientific Corporation | $1,684.24 | 2020-2025 | General - Pain Management, Intracept, Intracept Rf Probe |
| Vertiflex, INC. | $1,607.26 | 2019 | |
| Medtronic USA, INC. | $1,383.36 | 2019-2020 | |
| Abbvie INC. | $618.85 | 2021-2025 | |
| Si-Bone, INC. | $464.56 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $366.15 | 2019-2025 | Xtampza |
| Mml US, INC. | $194.84 | 2024-2025 | Reactiv8 |
| Pfizer INC. | $174.87 | 2019-2024 | |
| Biotronik Nro, INC. | $137.67 | 2025 | Prospera |
| Curonix LLC | $104.88 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $98.95 | 2021 | |
| Stryker Corporation | $73.09 | 2025 | Optablate, Mild Device Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $69.17 | 2020-2023 | Monovisc |
| Allergan, INC. | $63.40 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $42.84 | 2024-2025 | |
| Averitas Pharma INC. | $35.20 | 2023 | Qutenza |
| Novartis Pharmaceuticals Corporation | $33.97 | 2020-2021 | |
| Spinal Simplicity, LLC | $27.42 | 2023 | Ha Minuteman G3-R |
| Biodelivery Sciences International, INC. | $24.56 | 2020-2021 | |
| Acacia Pharma INC | $24.55 | 2021 | |
| Zyla Life Sciences, INC. | $22.20 | 2020 | |
| Merz Pharmaceuticals, LLC | $20.10 | 2023 | Xeomin |
| Saluda Medical Americas, INC. | $19.92 | 2025 | Evoke |
| Lilly USA, LLC | $18.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.20 | 2021 | |
| Horizon Therapeutics Plc | $14.97 | 2021 | |
| International Rehabilitative Sciences, INC | $14.73 | 2024 | Rs 4i Plus Sequential Stimulator |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.